美通社

2024-12-13 08:00

Heranova to Unveil HerResolve™, a Revolutionary Non-Invasive Endometriosis Test, at the Ovarian Club Asian Conference in Hong Kong

92% Diagnostic Accuracy with a Simple Blood Test for Early Diagnosis and Treatment of Endometriosis

HONG KONG, Dec. 13, 2024 /PRNewswire/ -- Heranova, a leader in women's health innovation, is excited to announce the launch of HerResolve™, a groundbreaking non-invasive test for endometriosis, at the 2024 Ovarian Club Asian Conference on December 14-15 at the Hong Kong Convention and Exhibition Centre.

This innovative test aims to transform the diagnosis and management of endometriosis, offering new hope for women worldwide. Endometriosis, a common and debilitating condition affecting millions, has historically presented significant diagnostic challenges. Traditional methods often require invasive procedures, leading to discomfort and risks for patients.

HerResolve™ meets this critical need by providing a convenient and accurate solution. A simple blood draw achieves an impressive 92% diagnostic accuracy, offering a non-invasive alternative for women experiencing symptoms such as pelvic pain, painful periods, or infertility.

HerResolve™ utilizes cutting-edge technology grounded in extensive research into the molecular pathways of endometriosis. By identifying clinically significant miRNA biomarkers and employing proprietary AI algorithms and advanced bioinformatics, the test converts complex medical data into clear "positive/negative" results. This provides physicians with reliable diagnostic information, enhancing both efficiency and accuracy.

"We recognize the complexity and urgency of diagnosing endometriosis," said Dr. Jonathan Zhao, CEO of Heranova. "HerResolve™ embodies years of dedicated research and innovation. It will transform the diagnostic landscape, enabling early and precise identification of the condition and empowering physicians to create personalized treatment plans, thereby advancing gynecological medicine."

Dr. Jonathan Zhao and Dr. Farideh Bischoff, Chief Medical Officer of Diagnostics at Heranova, will be present to engage with global experts and attendees, sharing insights into the technological advancements and clinical applications of HerResolve™.

During the conference in Hong Kong, Heranova will launch an early access program for HerResolve™. Interested parties are encouraged to visit the Heranova booth to discuss potential collaborations.

About Heranova

Heranova is a medical technology company committed to delivering comprehensive and innovative solutions for women's health challenges. By integrating diagnostics, therapeutics, medical devices, and data analysis, Heranova provides a one-stop solution for unmet needs in obstetrics and gynecology. Founded in March 2022 in Boston by experienced entrepreneurs and former multinational executives, Heranova operates on a US-Asia joint model, conducting simultaneous research, development, and commercialization.

For more information about Heranova and its products, please visit: www.heranova.com.

Media Contact: charmaine.ye@heranova.com

source: Heranova Lifesciences, Inc.

《說說心理話》心理急救II:幾個徵兆辨認身邊人需要心理支援!點樣對情緒進行急救、自我照顧?專家分享穩定情緒小練習► 即睇

人氣文章
財經新聞
評論
專題
專業版
HV2
精裝版
SV2
串流版
IQ 登入
強化版
TQ
強化版
MQ

【etnet 30周年】多重慶祝活動一浪接一浪,好禮連環賞!

【etnet30周年連環賞】睇住賞Maxcare美天復康寶(升級版) (價值HK$1,680)

etnet榮獲HKEX Awards 2023 「最佳證券數據供應商」大獎

回顧24 展望25

大國博弈

貨幣攻略

說說心理話

聖誕新年特輯

Watche Trends 2024

北上食買玩

Artcation

秋冬養生食療

消委會報告

山今養生智慧

輕鬆護老